Literature DB >> 18264138

Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.

Z Cai1, G Zhang, Z Zhou, K Bembas, J A Drebin, M I Greene, H Zhang.   

Abstract

2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB3. In our studies of epidermal growth factor receptor (EGFR)-p185(her2/neu) heterodimerization, we noted that 2C4 formed associations with the EGFR-p185(her2/neu) receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185(her2/neu), but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185(her2/neu) will emerge as the most potent targeted therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18264138      PMCID： PMC2819401          DOI： 10.1038/onc.2008.13

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  30 in total

1.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.

Authors:  D B Weiner; J Liu; J A Cohen; W V Williams; M I Greene
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

2.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

Authors:  Kathryn M Ferguson; Mitchell B Berger; Jeannine M Mendrola; Hyun Soo Cho; Daniel J Leahy; Mark A Lemmon
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.

Authors:  J A Cohen; D B Weiner; K F More; Y Kokai; W V Williams; H C Maguire; V A LiVolsi; M I Greene
Journal:  Oncogene       Date:  1989-01       Impact factor: 9.867

5.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

Authors:  J A Drebin; V C Link; D F Stern; R A Weinberg; M I Greene
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

6.  Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.

Authors:  James G Jackson; Patricia St Clair; Mark X Sliwkowski; Michael G Brattain
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

7.  Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene.

Authors:  J A Drebin; D F Stern; V C Link; R A Weinberg; M I Greene
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

8.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

Authors:  Matthew C Franklin; Kendall D Carey; Felix F Vajdos; Daniel J Leahy; Abraham M de Vos; Mark X Sliwkowski
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

9.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.

Authors:  M van de Vijver; R van de Bersselaar; P Devilee; C Cornelisse; J Peterse; R Nusse
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

10.  Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

Authors:  J A Drebin; V C Link; M I Greene
Journal:  Oncogene       Date:  1988-03       Impact factor: 9.867
View more
  22 in total

1.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.

Authors:  Nadège Gaborit; Christel Larbouret; Julie Vallaghe; Frédéric Peyrusson; Caroline Bascoul-Mollevi; Evelyne Crapez; David Azria; Thierry Chardès; Marie-Alix Poul; Gérard Mathis; Hervé Bazin; André Pèlegrin
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.

Authors:  Huihao Zhou; Zhao Zha; Yang Liu; Hongtao Zhang; Juanjuan Zhu; Siyi Hu; Guodong Shen; Liansheng Cheng; Liwen Niu; Mark I Greene; Maikun Teng; Jing Liu
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

4.  Two dimensions in targeting HER2.

Authors:  Mark M Moasser
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

Review 5.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors:  Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

Review 6.  Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

Authors:  Francisco J Esteva; Dihua Yu; Mien-Chie Hung; Gabriel N Hortobagyi
Journal:  Nat Rev Clin Oncol       Date:  2009-12-22       Impact factor: 66.675

Review 7.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

8.  scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.

Authors:  Zheng Cai; Ting Fu; Yasuhiro Nagai; Lian Lam; Marla Yee; Zhiqiang Zhu; Hongtao Zhang
Journal:  Cancer Res       Date:  2013-02-08       Impact factor: 12.701

9.  Targeting HER2 by Combination Therapies.

Authors:  Ana Ruiz-Saenz; Mark M Moasser
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

10.  HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.

Authors:  Yi Zhang; Lee Opresko; Harish Shankaran; William B Chrisler; H Steven Wiley; Haluk Resat
Journal:  BMC Cell Biol       Date:  2009-10-31       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.